HANSOH PHARMA(03692)

35.500-1.220-3.32%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Movement Alert｜HANSOH PHARMA Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Meets Broad Pharma Sector Weakness
  Market Focus · 09:49
  Movement Alert｜HANSOH PHARMA Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Meets Broad Pharma Sector Weakness
- Here's What Analysts Are Forecasting For Hansoh Pharmaceutical Group Company Limited (HKG:3692) After Its Half-Year Results
  Simply Wall St. · 08-29 06:17
  Here's What Analysts Are Forecasting For Hansoh Pharmaceutical Group Company Limited (HKG:3692) After Its Half-Year Results
- China's Zhaoke Ophthalmology H1 Revenue Rises
  Reuters · 08-28 21:24
  China's Zhaoke Ophthalmology H1 Revenue Rises
- China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales
  Reuters · 08-27
  China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales
- China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales
  Reuters · 08-27
  China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales
- Goldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results
  Stock News · 08-27
  Goldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results
- Why Hansoh Pharma Surged Over 16% After Its Earnings Report?
  Deep News · 08-27
  Why Hansoh Pharma Surged Over 16% After Its Earnings Report?
- Biocytogen Pharmaceuticals H1 Revenue up 51.6%
  Reuters · 08-27
  Biocytogen Pharmaceuticals H1 Revenue up 51.6%
- Hansoh Pharmaceutical Group Stock Advances 16% in Hong Kong
  Dow Jones · 08-27
  Hansoh Pharmaceutical Group Stock Advances 16% in Hong Kong
- China's Hansoh Pharmaceutical Jumps Most on Record on H1 Profit Growth
  Reuters · 08-27
  China's Hansoh Pharmaceutical Jumps Most on Record on H1 Profit Growth
- Movement Alert｜HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year
  Market Focus · 08-27
  Movement Alert｜HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year
- Stronger Half Year Earnings And Profitability Could Be A Game Changer For Hansoh (SEHK:3692)
  Simply Wall St. · 08-26
  Stronger Half Year Earnings And Profitability Could Be A Game Changer For Hansoh (SEHK:3692)
- Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand
  Reuters · 08-26
  Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand
- HANSOH PHARMA lowers CB conversion price to HK$56.54, potential share issuance up 1.5%
  Bulletin Express · 08-26
  HANSOH PHARMA lowers CB conversion price to HK$56.54, potential share issuance up 1.5%
- Hansoh Pharmaceutical Cuts Convertible Bond Conversion Price to Hk$56.54 Per Share
  Reuters · 08-26
  Hansoh Pharmaceutical Cuts Convertible Bond Conversion Price to Hk$56.54 Per Share
- China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%
  Reuters · 08-26
  China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%
- Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes
  Reuters · 08-26
  Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes
- Hansoh Pharma Declares HKD 0.285 Interim Dividend for First Half of 2026
  Bulletin Express · 08-26
  Hansoh Pharma Declares HKD 0.285 Interim Dividend for First Half of 2026
- Hansoh Pharma Reports Near 36% Rise in First-Half Profit
  Reuters · 08-26
  Hansoh Pharma Reports Near 36% Rise in First-Half Profit
- Hansoh Pharma Posts 35.82% Profit Surge in Interim Results
  Stock News · 08-26
  Hansoh Pharma Posts 35.82% Profit Surge in Interim Results
Company Profile
Company Name
HANSOH PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
- -
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
- 08-26
  Interim Report
  INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026
  INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026
- 04-28
  Annual Report
  ANNUAL REPORT 2025
  ANNUAL REPORT 2025

1D
5D
Day
Week
Month

Loading ...

High

36.620

Open

36.060

Volume%

0.85

Low

35.000

36.720

T/O Rate

0.11%

To The Moon

HANSOH PHARMA(03692)

Company Profile

Most Discussed